Building a Robust mRNA CDMO: Advancing Scalable and End-to-End Manufacturing Solutions

The demand for mRNA-based medicines and vaccines has surged in recent years, highlighting the need for a reliable, scalable, and end-to-end manufacturing ecosystem. As a dedicated mRNA CDMO, ARCALIS is committed to enabling global access to high-quality mRNA therapeutics through cutting-edge production capabilities. In this session, we will explore the critical components of an integrated mRNA manufacturing platform, including template DNA production, mRNA synthesis, and LNP formulation. We will also discuss how strategic partnerships and advanced technologies are shaping the future of mRNA medicine manufacturing. Join us to gain insights into ARCALIS’ approach to accelerating innovation while ensuring regulatory compliance, scalability, and efficiency in mRNA therapeutic production.